Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
Clinical trial NCT04223791 · COMPLETED
Trial details
- NCT number
- NCT04223791
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-18
- Primary completion
- 2021-08-26
- Enrollment
- 643
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.